Title: PO-030 : Application of Stopping Rule of Pegylated Interferon-Alpha 2a Therapy to Korean Patients with Chronic Hepatitis B
Abstract: Aims: In pegylated interferon-alpha 2a (PEG-IFN) of chronic hepatitis B (CHB), the decline of hepatitis B surface antigen (HBsAg) titers after 12-week therapy has been considered as a potent predictor that can determine discontinuation of therapy. In this study, we evaluated treatment response in Korean patients with CHB after 12-week PEG-IFN therapy.
Methods: 100 patients with CHB were prospectively analyzed from April 2015 to September 2016 in multi-centers. After 12-week use of PEG-IFN, we evaluated the changes of HBsAg, heapatitis B virus (HBV) DNA, and other liver-related markers in patients with CHB.
Results: Of 100 patients with CHB, heapatitis B e antigen (HBeAg)- positive patients were 75, and HBeAg-negative patients were 25. After 12-week PEG-IFN therapy, the number of HBeAg-positive patients with HBsAg less than 20,000 IU/mL was 61 (82.43%), and the number of HBeAg-negative patents with declined HBsAg titers or decreased HBV DNA levels more than 2 log IU/mL was 19 (76.00%). In HBeAg-positive patients, the decline of HBV DNA and HBsAg levels after 12 weeks was 1.83 ± 2.05 log10 IU/mL (p < 0.0001) and 6452.33 ± 11266.74 IU/mL (p <0.0001), respectively. In HBeAg-negative patients, the decrease of HBV DNA and HBsAg levels after 12 weeks was 2.55 ± 2.11 log10 IU/mL (p < 0.0001) and 1940.71 ± 5071.62 IU/mL (p < 0.0001), respectively. The number of patients with HBsAg titers less than 1,500 IU/mL after 12 weeks was 14 (18.92%) in HBeAg-positive patients and 17 (68.00%) in HBeAg-negative patients, respectively.
Conclusions: As applying 12-week stopping rule, early anti-viral response rate of PEG-IFN was confirmed in Korean patients with CHB, and we could apply this results to determine patients who will continue long-term PEG-IFN therapy in the early period of treatment.
Publication Year: 2017
Publication Date: 2017-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot